Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group
JOURNAL OF GYNECOLOGIC ONCOLOGY, vol.32, no.3, 2021 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 32 Issue: 3
- Publication Date: 2021
- Doi Number: 10.3802/jgo.2021.32.e37
- Journal Name: JOURNAL OF GYNECOLOGIC ONCOLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE
- Keywords: Recurrent Ovarian Cancer, Primary Platinum Resistance, Mono-chemotherapy, Anti-angiogenic Treatment, Sorafenib, Prognostic Factor
- Dokuz Eylül University Affiliated: No
Abstract
Objective: Patients with platinum-resistant ovarian cancer (PROC) have a high need for reliable prognostic markers. Since significance of primary platinum resistance (PPR) versus secondary platinum resistance (SPR) was identified for patients receiving anti-angiogenic therapy, it has not been confirmed for chemotherapy only.